safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis术后安全管理的人尿胰蛋白酶抑制剂肺癌特发性肺纤维化患者.pdfVIP

Safety of Postoperative Administration of Human Urinary Trypsin Inhibitor in Lung Cancer Patients with Idiopathic Pulmonary Fibrosis 1 1 2 2 1 Yoshikane Yamauchi , Yotaro Izumi *, Masanori Inoue , Hiroaki Sugiura , Taichiro Goto , Masaki 1 1 1 3 1 Anraku , Takashi Ohtsuka , Mitsutomo Kohno , Kenzo Soejima , Hiroaki Nomori 1 Department of Surgery, School of Medicine, Keio University, Tokyo, Japan, 2 Department of Diagnostic Radiology, School of Medicine, Keio University, Tokyo, Japan, 3 Department of Pulmonary Medicine, School of Medicine, Keio University, Tokyo, Japan Abstract Background: Patients with idiopathic pulmonary fibrosis (IPF) undergoing pulmonary resection for lung cancer carry risks of acute exacerbations of IPF (AE) postoperatively. Currently, agents which may attenuate AE are actively sought. Urinary trypsin inhibitor, ulinastatin, is a synthetic glycoprotein which may potentially inhibit various inflammatory factors associated with the development and progression of IPF. The present study was done to evaluate the effects of administration of high dose ulinastatin in lung cancer patients with IPF immediately following lung resection. Methods: Patients with IPFs radiologically diagnosed on high resolution CT, and histologically diagnosed resectable lung cancers, were eligible for the study. The effects of escalating doses of ulinastatin 3 6105 5 5 , 6 610 , and 9 610 units/body/day, administered postoperat